Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
shark cartilage extract AE-941 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| shark cartilage extract AE-941 | DRUG | - |
DISEASE CHARACTERISTICS: Histologically confirmed renal cell adenocarcinoma Disease progression within 16 weeks after first-line therapy, which included interleukin-2 and/or interferon Metastatic disease not amenable to surgery Measurable and/or evaluable disease No more than one line of prior antic...
Top 20 of 36 competitors
Shark cartilage extract AE-941 is an investigational small molecule being studied for the treatment of kidney cancer and multiple myeloma and plasma cell neoplasm. It has been evaluated in clinical trials for these oncology indications, though it is not approved and remains in clinical development.
Shark cartilage extract AE-941 is being developed by COSCIENS Biopharma Inc., a company listed on the stock exchange under the ticker CSCI. The company is conducting clinical research on this investigational oncology drug.
Shark cartilage extract AE-941 has completed a Phase 3 clinical trial for metastatic kidney cancer and a Phase 2 trial for relapsed or refractory multiple myeloma. It is an investigational drug and has not been approved by regulatory authorities.
Shark cartilage extract AE-941 has been studied in two completed trials: NCT00005995, a Phase 3 trial in patients with metastatic kidney cancer, and NCT00022282, a Phase 2 trial in patients with relapsed or refractory multiple myeloma. Both trials were conducted in Canada.
Yes, shark cartilage extract AE-941 is also known as AE-941. The drug is referred to by both names in clinical trial records, and both names refer to the same investigational oncology treatment.